These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 24300822)

  • 1. [Brain metabolism in multiple sclerosis: effects of neurotrophic therapy].
    Pukhov RV; Bisaga GN; Trufanov AG; Efimtsev AIu; Fokin VA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):97-104. PubMed ID: 24300822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of erhuangfang for relapsing multiple sclerosis.
    Zhou L; Fan Y
    Neurol Res; 2015 Jul; 37(7):633-7. PubMed ID: 25668581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI,
    Cambron M; Reynders T; Debruyne J; Reyngoudt H; Ribbens A; Achten E; Laureys G
    J Neurol; 2018 Nov; 265(11):2614-2624. PubMed ID: 30187159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis.
    Pascual AM; Martínez-Bisbal MC; Boscá I; Valero C; Coret F; Martínez-Granados B; Marti-Bonmati L; Mir A; Celda B; Casanova B
    Neurology; 2007 Jul; 69(1):63-7. PubMed ID: 17606882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis.
    Benedetti B; Rovaris M; Rocca MA; Caputo D; Zaffaroni M; Capra R; Bertolotto A; Martinelli V; Comi G; Filippi M
    Mult Scler; 2009 Jul; 15(7):789-94. PubMed ID: 19465450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
    Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy.
    Schocke MF; Berger T; Felber SR; Wolf C; Deisenhammer F; Kremser C; Seppi K; Aichner FT
    Neuroimage; 2003 Oct; 20(2):1253-63. PubMed ID: 14568494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapsing-remitting multiple sclerosis: metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: initial experience.
    He J; Inglese M; Li BS; Babb JS; Grossman RI; Gonen O
    Radiology; 2005 Jan; 234(1):211-7. PubMed ID: 15528260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
    Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Differences in the spectroscopy of the lesions of the remitting relapsing form of multiple sclerosis shown by magnetic resonance].
    Martínez-Bisbal MC; Celda B; Martí-Bonmat L; Casanova-Estruch B; Coret-Ferrer F
    Rev Neurol; 2002 May 1-15; 34(9):807-12. PubMed ID: 12134339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study.
    Blinkenberg M; Mathiesen HK; Tscherning T; Jønsson A; Svarer C; Holm S; Sellebjerg F; Paulson OB; Hanson LG; Sorensen PS
    Neurol Res; 2012 Jan; 34(1):52-8. PubMed ID: 22196862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Total brain T2-hyperintense lesion-volume and the axonal damage in the normal-appearing white matter of brainstem in early lapsing-remitting multiple sclerosis].
    Pascual-Lozano AM; Martínez-Bisbal MC; Boscá-Blasco I; Valero-Merino C; Coret-Ferrer F; Martí-Bonmatí L; Martínez-Granados B; Celda B; Casanova-Estruch B
    Rev Neurol; 2007 Oct 16-31; 45(8):468-73. PubMed ID: 17948212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proton magnetic-resonance spectroscopy in remitting and secondary-progressive multiple sclerosis].
    Pozdniakov AV; Tiutin LA; Bisaga GN; Odinak MM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(4):36-9. PubMed ID: 11490432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis.
    Gadea M; Martínez-Bisbal MC; Marti-Bonmatí L; Espert R; Casanova B; Coret F; Celda B
    Brain; 2004 Jan; 127(Pt 1):89-98. PubMed ID: 14506072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations.
    Gonen O; Moriarty DM; Li BS; Babb JS; He J; Listerud J; Jacobs D; Markowitz CE; Grossman RI
    Radiology; 2002 Oct; 225(1):261-8. PubMed ID: 12355014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.
    Kaiser CC; Shukla DK; Stebbins GT; Skias DD; Jeffery DR; Stefoski D; Katsamakis G; Feinstein DL
    J Neuroimmunol; 2009 Jun; 211(1-2):124-30. PubMed ID: 19446890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
    Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.